University of Colorado Cancer Center
Videos
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Selection of Bispecific Antibody Therapies or CAR T-Cell Therapy in Relapsed Lymphomas"
FEATURING
Manali Kamdar
- 165 views
- December 17, 2023
- 1
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Results From a Ph1 Study of the All-Oral Regimen of CC-486 and Venetoclax For R/R AML"
FEATURING
Maria Amaya
- 147 views
- December 14, 2023
University of Colorado Cancer Center
EGFR Exon 20 Insertion Mutations in NSCLC: Optimal and “Soon to Be Optimal” Therapy
FEATURING
Tejas Patil
- 177 views
- December 4, 2023
- 3
Insights from 2023 ASCO® Annual Meeting
Assessment and Decision Tools for Balancing Survival and Quality of Life
FEATURING
Elizabeth Kessler
- 80 views
- October 3, 2023
University of Colorado Cancer Center
Current 1L Approaches to ALK and ROS1 NSCLC
FEATURING
Tejas Patil
- 178 views
- July 18, 2023
- 3
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary Refractory/Early Relapsed DLBCL"
FEATURING
Manali Kamdar
- 622 views
- June 7, 2023
- 1
PrecisCa
The BRUIN Study: Pirtobrutinib in Mantle Cell Lymphoma
FEATURING
Manali Kamdar
- 190 views
- June 7, 2023
PrecisCa
Treatment Approach for Older Patients With Mantle Cell Lymphoma: A Discussion of the SHINE Trial
FEATURING
Manali Kamdar
- 213 views
- June 7, 2023
PrecisCa
The POLARIX Trial: Polatuzumab With R-CHP in DLBCL
FEATURING
Manali Kamdar
- 244 views
- June 7, 2023
PrecisCa
Updates From the ECHELON-1 Trial Utilizing Brentuximab in Hodgkin’s Lymphoma
FEATURING
Manali Kamdar
- 86 views
- June 7, 2023
Total Health
Sexual & Marital Dysfunction in Women With Gynecologic Cancer
FEATURING
Saketh Guntupalli
- 23 views
- May 31, 2023
Total Health
Management of Advanced NSCLC: IO, Targeted Therapy, and Beyond
FEATURING
Tejas Patil
- 268 views
- May 25, 2023
- 3
Total Health
Breast Cancer Genetics, Genomics, and Emerging Diagnostic Tools
FEATURING
Radhika Acharya-Leon
- 229 views
- May 24, 2023
- 6
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L Setting
FEATURING
Virginia Borges
- 1,493 views
- April 13, 2023
- 9
University of Colorado Cancer Center
Evolving Paradigms in the Management of Early-Stage NSCLC
FEATURING
Tejas Patil
- 205 views
- March 13, 2023
- 1
University of Colorado Cancer Center
Management of Patients With R/R MCL
FEATURING
Manali Kamdar
- 213 views
- October 11, 2022
University of Colorado Cancer Center
Cancer 'Super-Survivors': ALK+ NSCLC
FEATURING
Ross Camidge
- 941 views
- August 29, 2022
- 9
University of Colorado Cancer Center
Application and Development of ctDNA in Early Stage CRC
FEATURING
Christopher Lieu
- 122 views
- October 1, 2021
i3 Health
New Opportunities in Advanced KRAS Mutation-Positive NSCLC: Biomarkers & Genetic Testing
FEATURING
Ross Camidge,
Beth Sandy
- 165 views
- August 4, 2021
- 2
University of Colorado Cancer Center
Practical Principles of Biomarker Testing in aNSCLC: Overview of Current Actionable Oncogenes
FEATURING
Tejas Patil
- 304 views
- June 18, 2021
- 1
University of Colorado Cancer Center
Targeting mNSCLC: Alectinib & Crizotinib, Chemoimmunotherapy in the 1L Setting
FEATURING
Tejas Patil
- 199 views
- March 17, 2021
- 1
University of Colorado Cancer Center
KRAS-G12V-Mutant NSCLC: Is There Any Benefit With RAF/MEK Inhibitor Following FAK Inhibitor Defactinib?
FEATURING
Ross Camidge
- 449 views
- March 5, 2021
- 1
University of Colorado Cancer Center
KRAS-Mutated NSCLC Update: Are We Close to a Highly-Effective Targeted Therapy With AMG510 & MRTX849?
FEATURING
Jose Pacheco
- 409 views
- November 30, 2020
- 3
University of Colorado Cancer Center
mNSCLC Treatment: How Critical Is Molecular Profiling for Targeted Therapy Selection?
FEATURING
Tejas Patil
- 684 views
- November 25, 2020
- 3
University of Colorado Cancer Center
Brigatinib vs Crizotinib in Advanced ALK+ NSCLC: A Glimpse Into the Future of the 1st-Line ALK Inhibitor Therapy?
FEATURING
Ross Camidge
- 1,107 views
- February 5, 2020
- 6